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Abstract 
The European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE) was 
established after a successful grant application to the European Cooperation is Science and 
Technology (COST). This network aimed to assess the existing knowledge and/or experience on 
health care delivery for people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) 
in the European countries and worldwide, and to enhance coordinated research and health care 
provision in this field.  
The EUROMENE proposal, was based on the establishment of interrelated working groups (WGs), 
where the participants contributed with specific knowledge and viewpoints according to their 
specialties and/or areas of interest. In this paper we outline the work of a multidisciplinary team of 
researchers, including epidemiologists, clinicians, statisticians, biomedical scientist and heath 
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economists, who set out their recommendations to guide data acquisition for ME/CFS research, 
aiming to standardise data collection and  improve epidemiological research. 
Key words: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Data Collection 
Standardisation, Research Guidelines, Europe. 
 
Introduction 
The European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE) was 
established after a successful grant application to a continuous open call from the European 
Cooperation in Science and Technology (COST) – through the instrument named COST Action. 
 
Initially designed by a group of ME/CFS researchers and health professionals, the proposed network 
was submitted to COST in 2015 aiming to assess the existing fragmented knowledge and/or 
experience on health care delivery for people with Myalgic Encephalomyelitis/Chronic Fatigue 
Syndrome (ME/CFS) in the European countries and worldwide, and to enhance coordinated research 
and health care provision in this field.  
 
ME/CFS is characterised by intolerance to efforts expressed by profound or pathological fatigue, 
malaise and other symptoms aggravated by physical or cognitive efforts at intensities previously well 
tolerated by the individual. Intolerance to efforts may be experienced immediately or typically be 
delayed for hours or a day or two after exertion and is associated with slow recovery, which may 
extend to one or more days (post-exertional malaise (PEM) or aggravation of symptoms following 
exertion ( Carruthers et al., 2011; Carruthers, DeMeirleir, et al., 2003; Institute of Medicine (IOM), 
2015).  Other key symptoms include unrefreshing sleep, cognitive manifestations, orthostatic 
intolerance and pain, including muscle and joint pain and headaches.  The symptoms are persistent 
or recurrent over long periods of time, and lead to a significant reduction in previous levels of 
functioning. Diagnosis is clinical, owing to the absence of biomarkers, and based on detailed clinical 
history and physical examination by a competent clinician ( Carruthers et al., 2011; Carruthers, De 
Meirleir, et al., 2003). There is no causal treatment for the disease. With symptom-oriented support 
many improve with time or learn to manage their illness. There is little evidence on long term 
prognosis.  However, full recovery is not the norm, particularly in adults ( Carruthers, De Meirleir, et 
al., 2003; Institute of Medicine, 2015; Nacul et al., 2020). 
Prevalence rate have been estimated as between 0.2 and 0.7% (Bakken et al., 2014; Jason et al., 
1999; Nacul et al., 2011; Vincent et al., 2012) with incidence rate of 0.015 new cases/1000-year ( 
Nacul et al., 2011). This could represent between 1 million and over 5 million people, probably 
around 3 million in the European continent living with ME/CFS. However, there are no Europe-wide 
estimates of disease burden (Estévez-López et al., 2018).  A much larger number of people will have 
chronic fatigue for other reasons, and many of them will also be significantly incapacitated. At least 
2/3 of the cases are in women ( Nacul et al., 2011; Valdez et al., 2018) with young people in their 
most productive phases of life being preferentially affected. However, ME/CFS was reported in all 
age groups (Valdez et al., 2018). Quality of life of those with ME/CFS is on average lower than with 
other chronic or disabling diseases, such as MS (Kingdon et al., 2018), cancer, depression( Nacul et 
al., 2011), diabetes, epilepsy, or cystic fibrosis (Ingerski et al., 2010; Kennedy et al., 2010; Varni et al., 
2007), the latter being related to children (Winger et al., 2015). Economic costs are considerable 
(Hunter et al., 2017; Jason et al., 2008; Lloyd & Pender, 1992; Valdez et al., 2018), with repercussions 
for the individual affected and their families and society, as well as to educational and occupational 
services. 
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The methodological approach presented in the EUROMENE proposal, was based on the 
establishment of interrelated working groups (WGs), where the participants joining the network 
would contribute with specific knowledge and viewpoints according to their specialties and/or areas 
of interest. In this paper we outline the work of a multidisciplinary team of researchers, including 
epidemiologists, clinicians, statisticians, biomedical scientist and heath economists, who set out their 
recommendations to guide data acquisition for ME/CFS research, aiming to standardise data 
collection and improve epidemiological research. An overarching principle of the present work was 
to suggest tools for collecting standardised data on the presence and severity of cardinal ME/CFS 
symptoms and dysfunctions that may impose a burden on patients’ well-being and health-related 
quality of life. To ensure scalability of the suggested assessments, including applicability in 
population-based studies, most of them are based on self-reports. When circumstances (both 
resources and needs) allow it, additional objective measurements are suggested to obtain a more 
comprehensive picture of ME/CFS.     
ME/CFS Standardised Research Guide 
The process of standardising data collection tools across participating European countries involved 
discussions between working group members, followed by consultation with all EUROMENE 
members. Selection of data variables was based on the following criteria: freely available and easy to 
use, validated and relevant for ME/CFS research, and consistent with current international practice 
in research. Having in mind relevance beyond European countries, topic-driven data elements such 
as the Common Data Elements (CDE) Project developed by the National Institute of Neurological 
Disorders and Stroke (NINDS) for ME/CFS clinical research were reviewed 
(https://www.commondataelements.ninds.nih.gov/MECFS.aspx#tab=Data_Standards ).   
The discussion began with a review of the literature of the current landscape of international 
ME/CFS research (Estévez-López et al., 2018). Data collection tools presently used within 
participating European countries were outlined by country representatives. Working group members 
focussed on four core domain areas for data collection: (i) general core information, (ii) provisional 
and confirmed diagnosis, (iii) clinical assessment, and (iv) symptom profiling. Within each of these 
topic areas, the group deliberated and agreed on the most appropriate tools to be used to collect 
data. Where consensus could not be made, members wrote a report comparing those tools 
identified. Afterwards, these reports were discussed by the entire group in order to reach a 
consensus. 
Figure 1 outlines data domains to be considered in research. The steps are presented as an example. 
It should be noted that our recommendation is not to collect all data discussed, only that which is 
relevant to the purpose of the individual study. However, the use of the recommended data 
collection tools is essential for maintaining standardised methodologies when the same data are 
collected (e.g., the assessment of pain levels) by different research groups.   
Preprints (www.preprints.org)  |  NOT PEER-REVIEWED  |  Posted: 30 September 2020                   doi:10.20944/preprints202009.0744.v1
Figure 1: ME/CFS Standardised Research Guide 
 
1. General core information  
We recommend the collection of data related to socio-demographics and the general health history 
of the participants. The epidemiology working group refers to the socio-economic working group for 
detailed recommendations on the essential socio-demographic data to be collected (Pheby et al., 
2020). In brief, we recommend the collection of gender, date of birth, ethnicity, and level of 
education, as well as marital status, occupation, income, and living conditions. Given that data from 
different national health systems lack standardisation and are difficult to access, we agreed on the 
need to elaborate a set of standardised questions for self-reporting health history that includes a 
comprehensive assessment of previous and current ill-health to uncover potential co-morbidities, 
conditions that may justify an alternative diagnosis, and information regarding the onset of the 
disease (infectious vs non-infectious).  
 
2. Provisional diagnosis 
A probable or provisional diagnosis can be ascertained based on questionnaire response, although 
diagnosis confirmation will usually require further assessment or confirmation by a health 
professional with experience in ME/CFS, which is preferably done through a face-to-face encounter. 
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Two available questionnaires that have been used throughout the European participating countries 
to diagnose ME/CFS are the DePaul Symptom Questionnaire (DSQ) (Jason et al., 2015) and the UK 
ME/CFS Biobank Symptom Assessment (UKMEBSA) (Lacerda et al., 2017).  
The DSQ was developed as a standard questionnaire to consistently assess principal symptoms of 
ME/CFS when diagnosing. The DSQ is a 54-item self-report measure of ME/CFS symptomology, 
including frequency and severity of symptoms and using three subscales: neuroendocrine, 
autonomic, and immune symptoms. Symptom frequency over the past six months is rated on a 5-
point Likert-type scale ranging from (0) ‘none of the time’ to (4) ‘all of the time’. Correspondingly, 
each symptom’s severity over the past six months is also rated on a 5-point Likert-type scale ranging 
from (0) ‘symptom not present’ to (4) ‘very severe’. A composite score for each subscale, ranging 
from 0-16, is then obtained by multiplying the frequency and severity scores.  
The UKMEBSA was developed specifically for the recruitment of participants to the UK ME/CFS 
Biobank and designed to complement the clinical assessment in order to classify individuals 
according to a variety of ME/CFS case definitions. Most of the UKMEBSA items were taken from 
validated questionnaires and the symptom list is largely based upon the Canadian Consensus ( 
Carruthers et al., 2003), Institute of Medicine (Beyond Myalgic Encephalomyelitis/Chronic Fatigue 
Syndrome: Redefining an Illness, 2015) and CDC-1994 criteria ( Carruthers et al., 2003; Fukuda et al., 
1994; Lacerda et al., 2017). The UKMEBSA is a short questionnaire exploring the presence, duration 
and impact of fatigue and other symptoms, and includes a 58-item self-report on the presence of 
ME/CFS symptomology, and questions on the presence of diseases that often present with fatigue. It 
enables the screening of patients for ME/CFS diagnosis according to six different clinical criteria.  
To determine which questionnaire would be best for diagnosing cases of ME/CFS, we made a 
comparison between the DSQ and the UKMEBSA. Both questionnaires inquire about co-morbidities, 
capture possible exclusionary conditions, and can make a provisional diagnosis using either the CDC-
1994, the CCC 2003, or the IOM criteria. The major difference is that the DSQ also asks about 
severity and frequency of symptoms, while the UKMEBSA asks only about presence of symptoms, 
which make the latter simpler to use. Therefore, we recommend the choice of questionnaire to 
depend on the study in question.   
We note here that the clinical working group of the EUROMENE will be making recommendations on 
standardised diagnostic criteria and application of that criteria. The provisional diagnosis is intended 
as a systematic approach to ascertain cases of ME/CFS for research purposes. While clinical 
diagnostic criteria might be broader (less sensitive) or even different in the different participating 
countries, there is a need for a standardised research diagnostic criteria that is able to select a more 
homogenous group of patients in order to select more comparable participants across the settings ( 
Jason et al., 2017).  
3. Clinical assessment 
The clinical assessment is an essential part of the diagnosis workout (IOM, 2015) and is an aid to 
identify co-morbidities and exclusionary conditions that could otherwise explain the symptoms 
(Hives et al., 2017; Jason et al., 2010). Considering the lack of biomarkers, in addition to 
questionnaire, we suggest a brief clinical assessment to comply with the suggested diagnostic 
criteria. If participants have completed initial questionnaires prior to the assessment (Figure 1), the 
encounter is an opportunity to clarify answers given and to confirm or to explore reported 
symptoms in depth (Kingdon et al., 2018).  
The physical assessment may include: 
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- A general physical examination, which may be normal, even though some patients present 
with general aspect of tiredness or of being unwell. Specific signs may help differential 
diagnosis or co-morbidities.  e.g.  anaemia, jaundice, assessment of levels of hydration and 
nutritional status or any other sign that may suggest ill-health or specific pathology; paleness 
and cold extremities may be noted. 
- Anthropometric measures, including height and weight at a minimum. 
- Blood pressure and heart rate taken at one-minute intervals with the participant first lying 
down for five minutes and then standing still for up to ten minutes (or until no longer able), 
with consideration to dropping the first reading. For research with emphasis on autonomic 
function, a beat-to-beat blood pressure monitoring may be considered. Additionally, active 
standing (AS) provocation may be performed after 7-10 minutes of rest. The blood pressure 
response should be analysed for min. 2-3 minutes, if it is possible should be prolonged up to 
10-13 minutes to characterise postural orthostatic tachycardia syndrome (POTS). Patients 
with severe symptoms may be unable to be tested with these procedures. This procedure 
should be performed according to ANS examination.; 
- Pulse oximetry; 
- A specific examination covering main body systems (skin, head and neck, heart and 
circulation, respiratory, abdomen, and limbs) and could include neck palpitations, 
oropharynx, lymph nodes (neck, supra-clavicular, axillar), joints and neurological 
examination; the latter to include at a minimum the quick assessment of mental status using 
a validated questionnaire (for example the Mini-Mental State Examination (MMSE) or the 
Addenbrooke’s Cognitive Examination – ACE-III), coordination and gait, cranial nerves, 
cerebellar function, muscle strength and tone, sensory function, and reflexes. 
- A directed examination targeted according to general health history, findings from the 
general clinical examination and specific symptoms reported.  
- Hand grip strength, a component of physical fitness which is defined as a set of attributes 
that people have or achieve that relate to the ability to perform physical activities 
(Caspersen et al., 1985), is a powerful marker of health in both the general population 
(García-Hermoso et al., 2019; Harber et al., 2017; Ortega et al., 2008; Rodriguez-Ayllon et al., 
2019; Ruiz et al., 2008) and chronic diseases (Estévez-López et al., 2019; Kato et al., 2012; 
Ruiz et al., 2009). Field-based tests are often preferred for large-scale studies as they are 
valid and reliable as well as relatively cheap, safe, and easy to perform and score (Castro-
Piñero et al., 2019, 2017; Fernandez Santos et al., 2016). Among several possible field-based 
tests, the usefulness of the hand grip strength (a measurement of muscle strength) has been 
demonstrated in ME/CFS (Nacul et al., 2018). It reflects the force derived from the combined 
contraction of extrinsic hand muscles and reduced hand grip strength has been shown to be 
associated with disability and impaired health-related quality of life (Estévez-López et al., 
2015; Gavilán-Carrera et al., 2019; Park et al., 2017) .  In one study by Nacul et al, hand grip 
strength was found to be reduced in people severely affected with ME/CFS (bed- or house-
bound) compared with people mild/moderately affected (ambulatory), and with healthy 
controls (Nacul et al., 2018). When circumstances allow to do so, we recommend to 
objectively measure fitness state by the hand grip strength test (muscle strength) in ME/CFS 
in EUROMENE participating countries. 
Although there is no blood test to diagnose ME/CFS, the following routine blood tests are important 
to help identify other conditions and co-morbidities: a full blood count, calcium, glucose (either 
fasting or random glucose or HBA1c), urea and electrolytes, serum creatine kinase, serum ferritin, 
liver function tests (including total protein, albumin, globulin, bilirubin, alanine, transaminase, 
alkaline phosphatase), c-reactive protein or ESR, Immunoglobulin G/M/A, anti-nuclear antibodies, 
rheumatoid factor or anti-cyclic citrullinated peptide (anti-CCP) antibodies, thyroid function tests 
(including T3, T4, thyroid-stimulating hormone, and thyroid peroxidase antibody test), basal 
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cortisolemia, coeliac disease screening (e.g. tissue transglutaminase antibody), and B12 and folate 
concentrations. A urinalysis should also be performed; we recommend using ten-parameter test 
strips that measures blood, bilirubin, urobilinogen, ketone, protein, nitrite, glucose, PH, specific 
gravity, and leucocytes. Other tests may be required according to symptoms and clinical findings. 
4. Diagnosis confirmation  
The confirmation of the ME/CFS diagnosis is achieved by combining the use of a standard 
questionnaire (provisional diagnosis) and clinical assessment (identify co-morbidities and 
exclusionary conditions that could otherwise explain the symptoms). While further discussions are 
taking place across EUROMENE, with the leadership of the Clinical Working Group, we propose that 
any of the Canadian Consensus ( Carruthers et al., 2003), CDC-1994 (Fukuda et al., 1994) and the 
IOM (Institute of Medicine, 2015) criteria are acceptable for case diagnosis, although the 
combination of the Canadian Consensus and IOM criteria are preferable as these require post-
exertional malaise symptoms. We also note that combined use of these 3 criteria provides a more 
specific diagnosis, which will often be desirable for research purposes ( Nacul et al., 2017). In any 
case, irrespective of the choice of diagnostic criteria, which will be referred to the clinical working 
group, we recommend that ascertainment of diagnosis by multiple criteria is done and registered on 
the database, so that they may be referred to if needed (e.g. for further analyses). Those recruited 
or excluded from research studies that do not meet the chosen diagnostic criteria are referred to 
“non- ME/CFS cases”, or “non-ME/CFS chronic fatigue cases” if chronic fatigue is present. The latter 
may be either attributable to a specific alternative diagnosis (e.g. MS- or cancer- related CF) or be 
“life-style’ related or of “unknown cause”.  
5. Symptom profiling 
The majority of symptoms reported are post-exertional malaise, extreme fatigue, cognitive 
dysfunction, orthostatic intolerance, and impaired sleep (Twisk, 2015). To ensure feasibility in large-
scale research, the recommended tools rely on self-reports and are designed to assess a patient’s 
symptoms in two ways: (i) questionnaire-based symptom profiling and (ii) instrument-based 
symptom profiling. Additional tools for collecting data pertaining to symptom profiling are also 
recommended as resources allow. To do so, all ME/CFS research studies across participating 
countries of the EUROMENE network should use these as a guide to enhance comparability of data 
and interpretability of findings, keeping in mind that, depending on the aim of each study, not all the 
measurements are compulsory in every study.  
5.1. Questionnaire-based symptom profiling 
The questionnaires recommended in Table 1 are freely available for use. Where possible, 
epidemiological parameters of validity and reliability will be reported. These are intended as a guide 
and should be tailored for each population. We suggest questionnaires be validated in native 
languages, if necessary.  
Table 1. Recommended data collection tools for questionnaire-based profiling of post-exertional-
malaise, pain, neurological, neurocognitive, neuroendocrine, immune, sleep, autonomic function, 
emotional/behavioural, and quality of life symptoms  
Recommended data 
collection tool Symptom domains Description 












 measures presence and severity of 
symptoms in previous 7 days 
Fatigue Severity 
Scale (FSS) 
fatigue  9-item 
 measures impact of fatigue on activities and 
lifestyle 
 distinguishes fatigue in ME/CFS from fatigue 




Sleep   19-item, 5-supplementary for bed 
partners/roommates  
 measures 7 components of sleep quality 
over past 30 days 
 higher numbers indicate poorer sleep 
quality 
 reliable and valid in people with ME/CFS 
COMPASS-31 Autonomic function  31-item 
 measures 6 clinically relevant domains 
 internally consistent 
Beck Depression 




 measures major depression symptoms and 
their severity  











Mental health (Affect)  20-item, 10-item per each type of affect 
 Possible time-frames: ranging from state 
(right now) to trait (generally) 
Short Form 36-item 
Health Survey (SF-




 36-item  
 measures 8 domains of health-related 
quality of life and physical and mental 
summary components 
 used to discriminate different diseases and 
levels of severity 
 
 
Two available questionnaires that have been used throughout the European participating countries 
to ascertain ME/CFS diagnosis, based on profiling symptoms. These are the DePaul Symptom 
Questionnaire (DSQ) (Jason et al., 2015) and the UK ME/CFS Biobank Participant Questionnaire 
(UKMEBPQ) (Lacerda et al., 2017).  
General ME/CFS Questionnaires 
DePaul Symptom Questionnaire 
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The DSQ was developed as a standard questionnaire to consistently assess principal symptoms of 
ME/CFS when diagnosing. The DSQ is a 54-item self-report measure of ME/CFS symptomology, 
including frequency and severity of symptoms and using three subscales: neuroendocrine, 
autonomic, and immune symptoms. Symptom frequency over the past six months is rated on a 5-
point Likert-type scale ranging from (0) ‘none of the time’ to (4) ‘all of the time’. Correspondingly, 
each symptom’s severity over the past six months is also rated on a 5-point Likert-type scale ranging 
from (0) ‘symptom not present’ to (4) ‘very severe’. A composite score for each subscale, ranging 
from 0-16, is then obtained by multiplying the frequency and severity scores.  
UKMEB Participant Questionnaire 
The UKMEBPQ was developed by the UK ME/CFS Biobank. This questionnaire is used to characterise 
individuals according to a comprehensive array of variables, such as demographic, socio-economic, 
and severity of symptoms and dysfunctions. The UKMEBPQ is a short questionnaire exploring the 
presence, duration and impact of fatigue and other symptoms, and includes a 58-item self-report on 
the presence and the severity of ME/CFS symptomatology. Most of the items were taken from 
validated questionnaires and the symptom list is largely based upon the following diagnostic criteria: 
Canadian Consensus ( Carruthers et al., 2003), Institute of Medicine (Beyond Myalgic 
Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness, 2015) and CDC-1994 criteria ( 
Carruthers et al., 2003; Fukuda et al., 1994; Lacerda et al., 2017). It uses seven subscales of symptom 
clusters: post-exertional malaise, pain, sleep, autonomic dysfunction, neurocognitive dysfunction, 
neuroendocrine dysfunction, and immune dysfunction (Lacerda et al., 2018). Individuals answer 
“Absent”, “Mild”, “Moderate”, or “Severe” to a list of 58 symptoms and each symptom is assigned a 
value of 0 to 3. Scores are obtained by adding values within the symptom domains and standardising 
to a scale of 0 to 100, where “0” indicates no symptoms and “100” indicates the presence of severe 
symptoms.  
Both the DSQ and the UKMEBPQ have been widely used throughout the European participating 
countries to profile symptoms in ME/CFS research. When we compared the DSQ and the UKMEBPQ, 
it was found that they are broadly equivalent, except that the former enquires about symptoms in 
the previous six months and the latter enquires about symptoms in the previous seven days. The 
working group is of the view that a shorter period of recall, such as that offered by the latter (i.e in 
the last week) is preferable, to minimise recall bias and to enable repeated assessments over shorter 
than 6-month periods, also enabling to capture fluctuation of symptoms over shorter periods of 
time. Both the UKMEBPQ and DPQ capture data on other variables, such as demographic variables. 
While the former may be appropriate for European populations, some questions may need to be 
adapted to specific country variations, e.g. in relation to ethnicity and income.  
For symptom domains (post-exertional malaise, pain, neurocognitive dysfunction, neurological 
dysfunction, neuroendocrine dysfunction, immune dysfunction, and sleep dysfunction) where there 
are currently no validated and reliable questionnaires that meets our working group criteria for 
selection, we recommend the use of the UKMEBPQ. In studies where information on the 
retrospective period of 6-month is appropriate and desirable, such as in cross-sectional studies, then 
the DPQ may also be appropriate.  
 
Post-exertional malaise (PEM) is considered to be a hallmark symptom of ME/CFS and is related to 
main diagnostic criteria (Morris & Maes, 2013). It is characterised by the worsening of ME/CFS 
symptoms after minimal physical or mental exertion; this worsening can be delayed 24-72 hours or 
more (Arroll et al., 2014). The UKMEBPQ contains six items pertaining to PEM symptoms and may be 
used to ascertain severity of this symptom. The DSQ has several questions that are intended to 
assess PEM, but its description does not match that set out in the IOM or the CCC diagnostic criteria. 
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A poll of 750 patients by the Science For ME forum, a place for the patient community to discuss 
biomedical ME/CFS research, that compared the DSQ and IOM descriptions of PEM showed that 
most patients considered the IOM description to be more accurate (ScienceforME, 2018). 
 
Pain is a core symptom of ME/CFS. Indeed, 94% of those with ME/CFS report experiencing 
widespread muscle pain and 84% report joint pain (Meeus & Nijs, 2007). Symptoms of chronic pain 
can account for up to one third of impairments and restrictions in daily functioning in people with 
ME/CFS (Meeus & Nijs, 2007; van der Schaaf et al., 2017). Pain experienced in ME/CFS may vary 
from being a minor annoyance to being the most disabling symptom of the disease. The UKMEBPQ 
contains eight items that assess pain, although other studies where pain is a primary outcome may 
wish to include an objective measure using a validated instrument recommended in section 3.5.2.  
 
Neurological manifestations in ME/CFS may be chronic or sporadic with unpredictable cycles of 
severity (Chaudhuri & Behan, 2000). It is therefore imperative to capture the change in these 
symptoms. The UKMEBPQ contains nine items capable of profiling symptoms of neurological 
manifestations that can be detrimental to daily functioning.  
 
Neurocognitive impairment, which is commonly reported in ME/CFS, could have implications on 
daily living such as difficulty with school and/or employment (Shanks et al., 2013). The UKMEBPQ 
contains nine items related to neurocognitive symptoms to capture problems of memory and 
information processing that can impair quality of life and contribute to disability.  
 
Neuroendocrine abnormalities are often present in ME/CFS with symptoms across multiple organ 
systems and have been classified as “energy production/transportation impairments” (IOM, 2015). A 
greater percentage of people with ME/CFS experience symptoms such as intolerance to temperature 
extremes, unusually cold extremities, and changes in appetite compared with healthy controls ( 
Jason & Brown, 2013). There are six items in the UKMEBPQ to assess the presence and severity of 
neuroendocrine symptoms in ME/CFS research.  
 
Immunological dysfunction is associated with ME/CFS (Brenu et al., 2011; Hardcastle et al., 2015). 
Although immunity is best captured through laboratory tests, the UKMEBPQ includes seven items 
related to immune dysfunction (Table 2). Changes in the presence and severity of these symptoms 
can be analysed alongside follow-up blood tests for a comprehensive representation.  
 
Daytime sleepiness is not dozing behaviour but is related to fatigue and problematic sleepiness. 
Within the UKMEBPQ, there is the Epworth Sleepiness Scale consisting of eight questions 
participants must respond to on a 4-point scale (0-3) their usual chances of dozing off or falling 
asleep while engaged in different activities. The score is a sum of the eight items, where 0 indicates a 
low average sleep propensity in daily life and 24 indicates a high average. The internal consistency of 
this scale has been found to have a mean Cronbach’s alpha of 0.82 and the test-retest reliability has 




Fatigue is a major disabling symptom in ME/CFS and is notoriously difficult to define as it is non-
specific and highly subjective (Krupp et al., 1989). Numerous fatigue scales have been created, 
however, the Fatigue Severity Scale (FSS) is the most commonly used validated fatigue-specific 
questionnaire (Valko et al., 2008). The FSS is a 9-item measurement of the impact of fatigue on the 
patient’s activities and lifestyle over the preceding week and was developed and validated initially in 
people with multiple sclerosis and systemic lupus. Participants are asked to rate each item on a 7-
point Likert-type scale ranging from (1) ‘strongly disagree’ to (7) ‘strongly agree’. The FSS scores is 
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computed as the average of its nine items, with a minimum score being 1 and a maximum being 7 
and the higher the score, the greater the fatigue. The advantages of the FSS are that it is brief to 
administer (less than 5 minutes), it is capable of differentiating fatigue in ME/CFS from fatigue in 
multiple sclerosis as well as from fatigue in depression, and it is sensitive to treatment changes in 
ME/CFS (NINDS Common Data Elements, 2018).  
 
Sleep Quality assessment 
 
Sleep is essential for optimal health. In ME/CFS, unrefreshing sleep as well as disturbed or restless 
sleep is a prominent symptom (Rahman et al., 2011). We recommend the Pittsburgh Sleep Quality 
Index (PSQI), a free and easy to use questionnaire, in order to assess sleep quality over a one-month 
period of time (Buysse et al., 1989). The PSQI takes 5-10 minutes to complete and it has been shown 
to have good reliability and validity in clinical studies with a range of populations, including people 
with ME/CFS (Fontes et al., 2017; Mollayeva et al., 2016). The advantage of the PSQI is that many of 
the questions are familiar to people with ME/CFS who often experience the problems raised 
(NINDS). The limitation is that many may not recall awakening during the night or may not know 
what specifically awakened them in the night.  
The PSQI is a 19-item questionnaire, with five supplemental questions for bed partners or 
roommates. It consists of seven components of sleep quality over the past 30 days, including 
subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, 
use of sleep medication, and daytime dysfunction (Buysse et al., 1989). Each component score is 
rated on a 3-point Likert-type scale ranging from (0) indicating good sleep to (3) indicating poor 
sleep. The component scores are added to provide a global score ranging from 0-21, where higher 
numbers indicate poorer sleep quality. We recommend both the Epworth Sleepiness Scale within 
the UKMEBPQ and the PSQI, but one may be more desirable depending on the study question.   
Autonomic dysfunction assessment 
Autonomic dysfunction, which includes symptoms such as orthostatic intolerance, dizziness or light-
headedness when standing, palpitations, cold hands and feet, and gastric and irritable bowel type 
symptoms, is frequently reported by participants with ME/CFS and are all related to altered 
autonomic nervous system functioning. The COMPASS-31 questionnaire is validated tool to be used 
in ME/CFS that assesses six clinically relevant domains of autonomic function. It is a refined and 
markedly abbreviated scoring system, which examines six clinically relevant domains: orthostatic 
intolerance, vasomotor, secretomotor, pupillomotor, gastrointestinal, and bladder (NINDS Common 
Data Elements, 2018). Yes/No or Present/Absent questions are scored as 0/1 while Frequency, 
Severity, and Time course questions are scored on a 0-3 Likert scale. Scores are weighted for each 
domain and range from 0 to 100, where higher scores indicate more or more severe symptoms. 
The COMPASS-31 was designed to provide a global severity score and domain scores that are both 
clinically and scientifically relevant (Sletten et al., 2012). It demonstrates good internal validity 
(Cronbach’s alpha = 0.92), test-retest reliability (r(s)=0.89; p<0.001) and good convergent validity 
(r(s)=0.47; p<0.001) (NINDS Common Data Elements, 2018). We recommend its use to assess 
autonomic function of participants with ME/CFS in participating countries.  
 
Mental health assessment  
Depression. The BDI-II is a 21-item questionnaire, evaluating the presence and severity of signs of 
depression (Beck et al., 1996). Each item is rated on a 4-point Likert-type scale ranging from (0) 
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indicating symptom absent to (3) indicating severe symptoms. Thus, the total scores of the BDI-II 
range from 0 to 63, with higher scores meaning higher signs of depression. 
Anxiety. The State-Trait Anxiety Inventory (STAI) assesses the level of anxiety (Spielberger et al., 
1970). The STAI is a 20-item self-administered questionnaire, and its score ranges from 20 to 80, 
where higher scores indicate greater state anxiety. Participants rate how accurately statements 
describe their feelings on a 4-point Likert-type scale (range, from "not at all" to "very much so"). Two 
time-frames are possible for the STAI: the state version in which participants report how they feel 
"right now, that is, at this moment" and the trait version in which they report how they "generally" 
feel. According to the aim of the study, researchers should choose the time-frame version that best 
fit the research question. 
Affect. The Positive and Negative Affect Schedule (PANAS) assesses both positive and negative affect 
(Watson et al., 1988). The PANAS is a 20-item self-administered questionnaire, 10 to positive affect 
(e.g., enthusiastic) and 10 to negative affect (e.g., scared). The score ranges from 10 to 50, where 
higher scores indicate higher either positive affect or negative affect.  Participants rate to what 
extent statements describe their feelings on a 5-point Likert-type scale (range from "very slightly or 
not at all" to "extremely". Although there is a wide range of temporal instructions for the PANAS, the 
most common are "right now" and "in general"; i.e., state and trait directions. According to the aim 
of the study, researchers should choose the time-frame version that best fit the research question. 
Quality of life assessment  
 
Health-related quality of life has been shown to be lower in ME/CFS than in many other chronic 
conditions, including diabetes, stroke, osteoarthritis, rheumatoid arthritis, and even cancer (Falk 
Hvidberg et al., 2015; Kingdon et al., 2018). The RAND-36 (RAND corporation) is the publicly 
available version of the Short Form 36-item Health Survey (Optum, Inc., SF-36TM). Although an 
updated version of the SF-36TM is available (SF-36V2TM), all the 3 versions are similar and produce 
comparable scores (Laucis et al., 2015). 
 
All the versions of this scale (SF-36TM, SF-36V2TM, and RAND-36) measures health-related quality of 
health across three domains – functional status, well-being, and overall perceptions of health– with 
8 subscales including physical functioning, role limitations due to physical problems, bodily pain, 
general health perceptions, vitality, social functioning, role limitations due to emotional problems, 
and mental health (. Hays et al., 1993; Hays & Morales, 2001; Ware Jr. et al., 2007). From weighted 
sums in each subscale, two summary scales are derived, the physical component summary and the 
mental component summary, which give an indication of physical and mental capacity, respectively. 
Each scale is transformed into a 0-100 scale, where high scores indicate more disability. Scores are 
converted to z scores for comparison with the general population or other diseased populations, for 
which there is population-based normative data available.  
This scale is easy to administer (approximately 10 minutes) and is among the most widely used 
generic measure of health-related quality of life (R. Hays & Morales, 2001). The psychometric 
properties of the RAND-36 are adequate, clearly separating mental issues from physical issues 
(Gandek et al., 2004; R. Hays & Morales, 2001). We recommend the use of the RAND-36 for 
measuring health-related quality of life in ME/CFS in Europe, which is publicly accessible in the 
following link: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form.html.  
 
Clinical measurements - instrument-based symptom profiling 
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Table 1. Recommended data collection tools for instrument-based profiling of fatigue, pain, and 










 continuous scale anchored by 2 verbal descriptors 
of each extreme (no fatigue/pain vs worse/pain 
fatigue imaginable) 
 quantifiable measure of fatigue 
 valid and reliable  





heart rate and blood pressure measured at rest, then 
immediately upon standing and at 1-2 minute intervals 
for 10 minutes (or until no longer able) 
 
Visual Analog Scales 
Visual analogue scales (VAS) have become popular since first being validated (Hewlett et al., 2011) to 
use as quantitative measures to estimate subjective perceptions such as symptoms of fatigue 
because they are easily understood by participants, are quick to use and require very little reading 
skills. VAS are a continuous scale comprised of a horizontal line 100-mm in length and anchored by 
two verbal descriptors: (0) ‘no fatigue/pain at all’ and (100) ‘the worst imaginable fatigue/pain’. The 
patient is asked to place a line at the point that represents their fatigue/pain in the previous 24 
hours. Due to its simplicity and adaptability, VAS measurements of symptom intensity have been 
widely used in diverse adult populations; e.g. in rheumatic diseases, chronic hepatitis-C infection, 
and systemic lupus (Estévez-López et al., 2017; Hewlett et al., 2011). 
VAS have been shown to be a valid and reliable approach for having a rapid and quantitative 
assessment (Hewlett et al., 2011;Hawker et al., 2011). In the absence of a gold standards for 
measuring fatigue and pain, we recommended the use of VAS as standardised data collection tools 
for the instrument-based symptom profiling in people with ME/CFS.  
  
Active standing test  
Autonomic function is often altered in ME/CFS (Słomko et al., 2019). For instance, the experience of 
orthostatic intolerance is common in this population. Orthostatic intolerance is defined as the 
development of symptoms associated to changes in heart rate and blood pressure, when standing 
upright, which are relieved when reclining. We recommend the 10-minute standing test as a simple 
instrument-based tool to be used to capture orthostatic intolerance, and when feasible, we suggest 
extending the test to 20 minutes. Heart rate and blood pressure is measured at baseline while the 
person is supine for five minutes and again, at one or two-minute intervals, after passive standing up 
for up to 10 or 20 minutes, or until she or he can no longer tolerate the upright position (Reynolds et 
al., 2014). Capturing typical symptoms such as of dizziness, dyspnoea, and light-headedness 
simultaneously to an increase in pulse rate by at least 30 beats/min(adults) or to above 120 
beats/minute enables the suggestion of a diagnosis of postural orthostatic tachycardia syndrome 
(POTS), a common co-morbidity among people with ME/CFS. Postural hypotension is indicated by a 
drop in systolic blood pressure of at least 20 mmHg and/or a drop of diastolic blood pressure of at 
least 10 mmHg. 
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Additional tools for symptom profiling 
In order to have a comprehensive symptom profiling of ME/CFS, we agreed on the need to collect 
objective measurements of pain, autonomic function, physical activity and physical fitness. At the 
same time, we do recognise that these objective measurements require adequate equipment and 
resources, trained researchers, and time-availability, not only for the assessment but also for the 
dataset preparation. Thus, we suggest the following measurements only as complementary when 
ideal circumstances allow to do so.   
 











 non-invasive measure of autonomic nervous system 
imbalances 
 requires a heart rate monitor and program to analyse 




 non-invasive measure of physical activity, sedentary 
time and sleep 
 requires device to be used by participant through 
normal activity for ≥ 1 week  
 
Heart rate variability 
Heart rate variability (HRV) is an objective measurement of autonomic function by means. Analysing 
the variability between R waves (R-R interval) is a non-invasive indicator of autonomic dysfunction 
and has been associated with poor health (Evans et al., 2013; Meeus et al., 2013). The NINDS 
recommends a modified version that was described by Hyatt et al. in which the blood pressure is 
measured at 1-minute intervals, with the patient lying supine for the first five minutes and then 
standing up for ten minutes (or until no longer able) (Hyatt et al., 1975).  
Accelerometers 
Accelerometers provide objective measurements of physical activity, sedentary time and sleep (i.e., 
all the possible 24-h movement-related behaviours) (Tremblay et al., 2017.). Accelerometers are 
increasingly being used to objectively measure physical activity, sedentary time and sleep in diverse 
populations (Acosta et al., 2018; Migueles et al., 2018; Rodriguez-Ayllon et al., 2019; Segura-Jiménez 
et al., 2019), including ME/CFS (Meeus 2011, Rowlands 2016, Scheibenbogen 2018).  
Physical activity and sedentary time are two independent yet related behaviours that occupy all 
waking hours of a day. Physical activity is any bodily movement that increases energy expenditure 
above resting energy expenditure (Caspersen et al., 1985; Tremblay et al., 2017). Sedentary time is 
the time spent in any waking behaviour and does not increase energy expenditure substantially 
while in a sitting, reclining or lying posture.  
Although accelerometers were originally developed to measure physical activity, new technical and 
engineer applications have also made possible to evaluate sleep patterns. To the best of our 
knowledge, accelerometers have been used to objectively measure sleep in samples from the 
general population (e.g., from youths to older adults) (Adelantado-Renau et al., 2019; Cadenas-
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Sanchez et al., 2016; Fang et al., 2019) and chronic populations (e.g., diabetes and fibromyalgia) 
(Rosique-Esteban et al., 2018; Segura-Jiménez et al., 2015) but not in ME/CFS yet.  
When circumstances allow to do so, we recommend to use accelerometers to objectively measure 
physical activity, sedentary time and sleep (i.e., all the possible 24-h movement-related behaviours) 
in ME/CFS in EUROMENE participating countries. As their utilization requires standardized data 
collection and processing of collected data (Migueles et al., 2017, 2018) , we warrant a further 
EUROMENE consensus on these issues. 
Final Considerations 
Through this research guide, we have set out minimum standards of data collection and offer 
recommendations for additional tools that can be used to enhance ME/CFS, where resources and 
local needs allow. We describe which general core information is essential to collect, how a 
provisional ME/CFS diagnosis should be made, and what assessments are used to confirm that 
diagnosis. We then set out questionnaire- and instrument-based tools used to profile symptoms and 
that an ME/CFS diagnosis is supported by the CDC- 1994, the CCC 2003, and/or the IOM criteria.  
These questionnaires are freely available and easy to use, many but not all have been fully validated. 
They are easy to apply and deemed relevant for ME/CFS research, while consistent with current 
research practice. Given that for some tools there is only preliminary evidence of validity and 
reliability, to confirm their psychometrical properties in ME/CFS is warranted. Likewise, in Europe 
there co-exists a large number of languages and cultures for which questionnaires will need to be 
tailored for and validated in. Thus, we hope that the suggested tools will be translated to the 
language of European participating countries.  
The suggested additional tools may provide valuable information in addressing a wide number of 
research questions. For instance, in case and control designs, the handgrip strength test could help 
to distinguish between people with and without ME/CFS and levels of severity of the disease; as it 
has been showed in fibromyalgia (Aparicio et al., 2011). In longitudinal studies, objectively measured 
physical activity might help to predict the progression of ME/CFS patients.  
Overall, the simplicity of the suggested tools and because they are currently used in Europe, the 
present work will enable us to take a pragmatic decision to encourage participating European 
countries to adopt this guide. This will enable users to synchronise the identification of cases, data 
collection, and input of data and samples relating to ME/CFS research. By doing so, it will be possible 
to create an international database for collecting consistent and comparable epidemiological data to 
further facilitate scientific and clinical research. The CDE Project developed by the NINDS for ME/CFS 
research also outlines uniform formats by which clinical data can be systematically collected, 
analysed and shared across the research community. Many of the tools suggested by the NINDS are 
also recommended in this research guide; these include the clinical assessment (both physical 
examination and routine blood tests), the passive standing test to measure autonomic function, the 
RAND-36 to assess health-related quality of life, the PSQI to evaluate sleep quality, and the FAS and 
the FSS to quantify symptoms of fatigue. However, the adoption of the standardised data collection 
tools in the EUROMENE network also takes into account existing research practices among 
participating countries. This will make data systems and their use consistent with pre-existing 
approaches to data collection by participating countries, which have already been collecting data in 
standardised ways, while still allowing comparability with CDEs used in other parts of the world.  
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